Core Viewpoint - Contineum Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of its Class A common stock at $12.25 per share, indicating a strategic move to raise capital for its clinical-stage biopharmaceutical initiatives [1] Company Summary - The company is focused on developing differentiated therapies targeting neuroscience, inflammation, and immunology (NI&I) indications, highlighting its commitment to advancing treatment options in these critical areas [1] - The public offering consists of 7,346,938 shares, which reflects an increase in the size of the offering, suggesting strong investor interest and confidence in the company's future prospects [1] - Contineum has provided underwriters with a 30-day option, which may allow for additional shares to be sold, further indicating the company's proactive approach to capitalizing on market conditions [1]
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering